Showing results (361-370 of 548) with videos related to
Sort By:
Pageof 55
Therapeutic Advances in Psychopharmacology|January 20, 2017
Switching away from pipotiazine palmitate: a naturalistic studyFeras Ali MustafaTherapeutic Advances in Psychopharmacology|February 6, 2015
Characteristics of bipolar disorder patients treated with immediate- and extended-release quetiapine in a real clinical setting: a longitudinal, cohort study of 1761 patientsAndreas Carlborg, Marcus Thuresson, Lena Ferntoft, et al.Therapeutic Advances in Psychopharmacology|February 6, 2015
Poor monitoring of physical health in patients referred to a mood disorders serviceDavid Lack, Richard I G Holt, David S BaldwinTherapeutic Advances in Psychopharmacology|October 22, 2021
Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrationsAmir Krivoy, Eromona Whiskey, Henrietta Webb-Wilson, et al.Therapeutic Advances in Psychopharmacology|November 21, 2022
Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulationOlivier Corbeil, Anne-Marie Essiambre, Laurent Béchard, et al.Therapeutic Advances in Psychopharmacology|February 10, 2023
Enduring neurological sequelae of benzodiazepine use: an Internet surveyChristy Huff, A J Reid Finlayson, D E Foster, et al.Therapeutic Advances in Psychopharmacology|February 23, 2023
Serum cytokine variations among inpatients with major depression, bipolar disorder, and schizophrenia versus healthy controls: a prospective 'true-to-life' studyAntonio Augusto Schmitt Junior, Lucas Primo de Carvalho Alves, Barbara Larissa Padilha, et al.Therapeutic Advances in Psychopharmacology|February 16, 2026
Healthcare resource savings from administering paliperidone palmitate once every 3 months instead of once every month for schizophrenia: a 12-month mirror-image analysis of real-world population-based dataKe-Fei Wu, Ya-Hui Yang, Chuan-Sheng Hung, et al.Therapeutic Advances in Psychopharmacology|February 16, 2026
Impact of treatment with long‑acting injectable antipsychotics on hospitalization and relapse rates in schizophrenia spectrum disorders: a 3‑year follow-up mirror‑image studyRenato de Filippis, Matteo Aloi, Alfredo Cimino, et al.Therapeutic Advances in Psychopharmacology|November 18, 2024
Prevalence and risk factors of PTSD symptoms: a 3-month follow-up studyZhilei Shang, Xiao Pan, Suhui Cheng, et al.Pageof 55